CGM Technology is likely to provide cost savings in both the short and longer term:
Savings in the short term will be found through reduced hospital and healthcare costs as a result of fewer incidences of severe hypoglycaemia;
Savings in the longer term will be found as a result of reduced rates of macro- and microvascular complications, greater wellbeing and increased productivity of both the T1D and immediate family members. Some of these costs are hard to quantify however research suggests the cost of a severe hypoglycaemic event, including healthcare and productivity costs, is around $18,257 for all people and $14,944 for people aged 12 years and older.16 Around 20 per cent of people with type 1 diabetes experience at least one severe hypoglycaemic event in a six-month period.
Diabetes complications substantially increase the cost of providing healthcare to a person with diabetes. Evidence shows the cost of providing healthcare to a person with diabetes and macro- vascular and microvascular complications rises by $11,287 per annum compared to a person with diabetes and no complications.
Extensive evidence suggests CGM can contribute to better blood glucose control which substantially decreases an individual’s likelihood of developing complications. The potential savings would certainly offset the investment for CGM sensors.
16 Ly, Trang T., Alan J.m. Brnabic, Andrew Eggleston, Athena Kolivos, Margaret E. Mcbride, Rudolf Schrover, and Timothy W. Jones. “A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes.” Value in Health: 561-69. Print.
17 Colagiuri S, Brnabic A, Gomez M, Fitzgerald B, Buckley A, Colaguir R. DiabCo$t Australi Type 1: Assessing the burden of Type 1 Diabetes in Australia. Diabetes Australia, Canberra, November, 2009.